There was a significantly higher percentage of ATN in the kidneys in the CIS-treated GAL-3 KO mice than in the CIS-treated Gal-3 wild-type mice (p < 0.01) (Figure 2I). This evidence concerns the gene TYR and in situ carcinoma.